These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 15491334)

  • 1. Monitoring of enoxaparin level using citrated clotting time during percutaneous coronary intervention.
    Díez JG; Cheong BY; O'Meallie LP; Alt EU
    J Interv Cardiol; 2004 Oct; 17(5):307-13. PubMed ID: 15491334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention.
    Chen WH; Lau CP; Lau YK; Ng W; Lee PY; Yu CM; Ma E
    J Invasive Cardiol; 2002 Aug; 14(8):439-42. PubMed ID: 12147872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions.
    Aslam MS; Sundberg S; Sabri MN; Cooke D; Lakier JB
    Catheter Cardiovasc Interv; 2002 Oct; 57(2):187-90. PubMed ID: 12357518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study.
    Martin JL; Fry ET; Sanderink GJ; Atherley TH; Guimart CM; Chevalier PJ; Ozoux ML; Pensyl CE; Bigonzi F
    Catheter Cardiovasc Interv; 2004 Feb; 61(2):163-70. PubMed ID: 14755805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory.
    Marmur JD; Lakhani M; El Rouby S; Cavusoglu E
    J Invasive Cardiol; 2008 Sep; 20(9):449-54. PubMed ID: 18762674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Feit A; Battala VR; Cavusoglu E
    J Invasive Cardiol; 2008 Jul; 20(7):323-7. PubMed ID: 18599887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial.
    Cohen M; Levine GN; Pieper KS; Lan L; Antman EM; Aylward PE; White HD; Kleiman NS; Califf RM; Mahaffey KW;
    Catheter Cardiovasc Interv; 2010 May; 75(6):928-35. PubMed ID: 20432399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin.
    Zalc S; Lemos PA; Esteves A; Ribeiro EE; Horta P; Nicolau JC; Ramires JA; Cohen M; Martinez EE
    J Invasive Cardiol; 2006 Feb; 18(2):45-8. PubMed ID: 16446514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration.
    Cavusoglu E; Lakhani M; Marmur JD
    J Invasive Cardiol; 2005 Aug; 17(8):416-21. PubMed ID: 16079447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
    Montalescot G; Cohen M; Salette G; Desmet WJ; Macaya C; Aylward PE; Steg PG; White HD; Gallo R; Steinhubl SR;
    Eur Heart J; 2008 Feb; 29(4):462-71. PubMed ID: 18276619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
    White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Steinhubl S; Montalescot G
    Am Heart J; 2009 Jan; 157(1):125-31. PubMed ID: 19081408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test.
    Silvain J; Beygui F; Ankri A; Bellemain-Appaix A; Pena A; Barthelemy O; Cayla G; Gallois V; Galier S; Costagliola D; Collet JP; Montalescot G
    J Am Coll Cardiol; 2010 Feb; 55(7):617-25. PubMed ID: 20170785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enoxaparin and percutaneous coronary intervention: a Canadian perspective.
    Fitchett D; Welsh R; Langer A; Goodman S
    Can J Cardiol; 2005 May; 21(6):501-7. PubMed ID: 15917879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial.
    Gallo R; Steinhubl SR; White HD; Montalescot G;
    Catheter Cardiovasc Interv; 2009 Feb; 73(3):319-25. PubMed ID: 19213086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.
    Ma JM; Jackevicius CA; Yeo E
    Ann Pharmacother; 2004 Oct; 38(10):1576-81. PubMed ID: 15328396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical issues on the use of enoxaparin in elective and emergent percutaneous coronary intervention.
    Díez JG
    J Invasive Cardiol; 2008 Sep; 20(9):482-9. PubMed ID: 18762681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
    Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
    Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
    Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
    J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enoxaparin experience in percutaneous coronary intervention.
    Somani V; Trivedi S
    J Indian Med Assoc; 2008 Jan; 106(1):12-5. PubMed ID: 18705262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis.
    Sanchez-Pena P; Hulot JS; Urien S; Ankri A; Collet JP; Choussat R; Lechat P; Montalescot G
    Br J Clin Pharmacol; 2005 Oct; 60(4):364-73. PubMed ID: 16187968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.